Myanmar Health Sciences Research Journal
Volume 28, Number 3
TITLE: Assessment of Serum HER2/neu by using ELISA Method in Breast Cancer Patients, Yangon General Hospital, Myanmar
AUTHOR: Zin Zin Thu, Khin Saw Aye, Myo Myint Maw, Ohnmar, Aye Mya Khine, Ni Ni Win, Aye Myint Oo & Kyaw Zin Thant
SOURCE: Myanmar Health Sciences Research Journal, Vol. 28, No. 3, 2016
ABSTRACT: In recent years, the HER2/neu oncoprotein has emerged as an important cellular target for the development of a variety of new cancer therapies and HER2/neu testing has been recommended in breast cancer patients to assess the prognosis and suitability of therapeutic agents. The aim of this study was to perform, for the first time, serum HER2/neu level testing in breast cancer patients in Myanmar. The research study was carried out at the Medical Oncology Ward, Yangon General Hospital. A total of 61 newly diagnosed female breast cancer patients of ages between 29 to 78 years were included in this study. Serum HER2/neu level in these patients was analyzed by enzyme-linked immunosorbent assay (ELISA). Out of 61 patients, 3.3% (2/61) were found with In-situ (non-invasive) breast carcinoma and 96.7% (59/61) had the invasive (infiltrative) breast carcinoma. Among the patients with invasive (infiltrative) breast carcinoma, 40.7% (24/59) were found with metastatic lymph nodes. Serum HER2/neu was positive (more than 15 ng/ml) in 4.9% (3/61) and negative (less than 15 ng/ml) in 95.1% (58/61). All three patients (3/3; 100%) with serum HER2/neu positive results suffered from invasive (infiltrative) breast carcinoma and two of these patients (2/3; 66.7%) had metastatic lymph nodes.This is the first study in Myanmar of serum HER2/neu detection in breast cancer patients. This study highlights the potential role of serum HER2/neu analysis in assessing the prognosis and suitability of targeted therapy in breast cancer patients in Myanmar.
SUBJECT HEADINGS: Breast cancer, Serum HER2/neu, Myanmar